The OMNI Surgical System facilitates a minimally invasive glaucoma surgery (MIGS) procedure that does not require an implant and targets three areas of outflow resistance associated with glaucoma.

In a challenging market environment, Sight Sciences , Inc. (NASDAQ:SGHT) stock has touched a 52-week low, with shares falling to $2.54. With a market capitalization of $130.44 million and an ...

Sight Sciences’ management is scheduled to present on Thursday, February 27, 2025, at 7:15 am PT / 10:15 am ET. Interested parties may access a live and archived webcast of the fireside chat on the ...

Moreover, a recent study has demonstrated the effectiveness of the company's OMNI Surgical System in reducing intraocular pressure in patients with primary open-angle glaucoma. UBS has initiated ...

It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment ...

9th Military Vision Symposium on Novel Technology and Vision Restoration hosted by Harvard Medical School Department of Ophthalmology and Mass Eye and Ear, February 27-28, 2025, at the Starr Center ...